BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27246829)

  • 41. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.
    Wiendl H; Mitsdoerffer M; Schneider D; Melms A; Lochmuller H; Hohlfeld R; Weller M
    Brain; 2003 May; 126(Pt 5):1026-35. PubMed ID: 12690043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo.
    Stoppa I; Gigliotti CL; Clemente N; Pantham D; Dianzani C; Monge C; Puricelli C; Rolla R; Sutti S; Renò F; Boldorini R; Boggio E; Dianzani U
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
    Fu T; He Q; Sharma P
    Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
    Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
    Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
    Abdel-Rahman SA; Świderek K; Gabr MT
    RSC Med Chem; 2023 Sep; 14(9):1767-1777. PubMed ID: 37731692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
    Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
    J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ICOS is required for the generation of both central and effector CD4(+) memory T-cell populations following acute bacterial infection.
    Marriott CL; Carlesso G; Herbst R; Withers DR
    Eur J Immunol; 2015 Jun; 45(6):1706-15. PubMed ID: 25754933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CXCR5 and ICOS expression identifies a CD8 T-cell subset with T
    Le KS; Amé-Thomas P; Tarte K; Gondois-Rey F; Granjeaud S; Orlanducci F; Foucher ED; Broussais F; Bouabdallah R; Fest T; Leroux D; Yadavilli S; Mayes PA; Xerri L; Olive D
    Blood Adv; 2018 Aug; 2(15):1889-1900. PubMed ID: 30087107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles.
    Clemente N; Boggio E; Gigliotti LC; Raineri D; Ferrara B; Miglio G; Argenziano M; Chiocchetti A; Cappellano G; Trotta F; Caldera F; Capucchio MT; Yagi J; Rojo MJ; Renò F; Cavalli R; Dianzani C; Dianzani U
    J Control Release; 2020 Apr; 320():112-124. PubMed ID: 31962094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
    Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
    Front Immunol; 2022; 13():992614. PubMed ID: 36119089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
    Solinas C; Gu-Trantien C; Willard-Gallo K
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.
    He M; Wang Y; Shi WJ; Wang SJ; Sha HF; Feng JX; Wang J
    J Dig Dis; 2011 Oct; 12(5):393-400. PubMed ID: 21955433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of T-regulatory cells in B-cell non-Hodgkin's lymphoma.
    Baraka A; Salem HM
    Egypt J Immunol; 2011; 18(2):23-30. PubMed ID: 23082467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-infiltrating mast cells stimulate ICOS
    Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
    J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.
    Sakthivel P; Grunewald J; Eklund A; Bruder D; Wahlström J
    Clin Exp Immunol; 2016 Feb; 183(2):294-306. PubMed ID: 26415669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human regulatory T cells suppress proliferation of B lymphoma cells.
    Grygorowicz MA; Biernacka M; Bujko M; Nowak E; Rymkiewicz G; Paszkiewicz-Kozik E; Borycka IS; Bystydzienski Z; Walewski J; Markowicz S
    Leuk Lymphoma; 2016 Aug; 57(8):1903-20. PubMed ID: 26758248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer.
    Huang XM; Liu XS; Lin XK; Yu H; Sun JY; Liu XK; Chen C; Jin HL; Zhang GE; Shi XX; Zhang Q; Yu JR
    Cancer Sci; 2014 Feb; 105(2):150-8. PubMed ID: 24261990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of polymorphisms in the ICOS and ICOSL genes with the pathogenesis of autoimmune thyroid diseases.
    Yoshie N; Watanabe M; Inoue N; Kawaguchi H; Hidaka Y; Iwatani Y
    Endocr J; 2016; 63(1):61-8. PubMed ID: 26560438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aberrant ICOS
    Kälble F; Mai C; Wagner M; Schober L; Schaier M; Zeier M; Spratte J; Fluhr H; Steinborn A
    Am J Reprod Immunol; 2016 Nov; 76(5):415-425. PubMed ID: 27650411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.